Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.blissgvs.com | |
Market Cap | 1,424.07 Cr. | |
Enterprise Value(EV) | 1,348.32 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 8.43 | Trailing Twelve Months Ending 2023-09 |
Price-Earning Ratio (PE) | 16.13 | Trailing Twelve Months Ending 2023-09 |
Industry PE | 38.52 | Trailing Twelve Months Ending 2023-09 |
Book Value / Share | 88.96 | Trailing Twelve Months Ending 2023-09 |
Price to Book Value | 1.53 | Calculated using Price: 136.05 |
Dividend Yield | 0.37 | Period Ending 2023-03 |
No. of Shares Subscribed | 10.47 Cr. | 104,672,822 Shares |
FaceValue | 1 | |
About Bliss GVS Pharma Ltd. | ||
It is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company's most unique product is ‘Today Vaginal Contraceptive', a safe female contraceptive aimed at furthering Planned Parenthood and is also an established method for preventing conception. Bliss also manufactures to US specification vaginal pessaries of Clotrimazole & Povidone Iodine in addition to Anal Suppositories for treatment of piles. The company also manufacture wide range of Pessary Formulations, Suppository Formulations, Calcium Preparation, Protein Powders, Iron Preparation, Antibiotics, Analgesic & Antipyretics, Respiratory, Anti-inflammatory, Dermatological Preparations, Anti-Diarrhoeal products. |
1 Day |
|
+5.21% |
1 Week |
|
-3.52% |
1 Month |
|
+20.81% |
3 Month |
|
+39.18% |
6 Month |
|
+80.34% |
1 Year |
|
+84.56% |
2 Year |
|
+35.42% |
5 Year |
|
-2.71% |
10 Year |
|
+254.95% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 19.74 | 26.73 | 25.06 | 17.34 | 21.43 | 13.79 | 9.64 | 2.88 | 9.11 | |
Return on Capital Employed (%) | 23.57 | 32.07 | 31.06 | 24.61 | 26.58 | 17.02 | 12.49 | 6.37 | 12.22 | |
Return on Assets (%) | 9.01 | 13.04 | 11.88 | 9.42 | 14.35 | 9.86 | 7.03 | 2.12 | 6.78 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 337 | 413 | 487 | 536 | 646 | 736 | 808 | 819 | 884 | 930 | |
Non Curr. Liab. | 68 | 50 | 33 | 13 | 38 | 46 | 45 | 29 | 43 | 62 | |
Curr. Liab. | 243 | 379 | 437 | 299 | 207 | 231 | 204 | 233 | 193 | 172 | |
Minority Int. | 15 | 33 | 66 | 11 | 14 | 15 | 20 | 28 | 34 | 33 | |
Equity & Liab. | 662 | 874 | 1,023 | 860 | 905 | 1,027 | 1,077 | 1,109 | 1,154 | 1,197 | |
Non Curr. Assets | 245 | 291 | 457 | 170 | 211 | 257 | 312 | 332 | 456 | 451 | |
Curr. Assets | 417 | 583 | 566 | 690 | 693 | 770 | 765 | 777 | 697 | 747 | |
Misc. Exp. not W/O | 0 | ||||||||||
Total Assets | 662 | 874 | 1,023 | 860 | 905 | 1,027 | 1,077 | 1,109 | 1,154 | 1,197 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09 Rs. Cr. TTM |
Net Sales | 407 | 547 | 798 | 815 | 899 | 689 | 577 | 747 | 752 | 762 | |
Other Income | 20 | 24 | 13 | 27 | 38 | 39 | 22 | 31 | 18 | 26 | |
Total Income | 427 | 571 | 811 | 841 | 936 | 728 | 599 | 779 | 769 | 788 | |
Total Expenditure | -304 | -391 | -596 | -618 | -741 | -566 | -471 | -629 | -634 | -629 | |
PBIDT | 124 | 180 | 215 | 224 | 195 | 163 | 129 | 150 | 135 | 159 | |
Interest | -16 | -19 | -20 | -23 | -4 | -8 | -7 | -5 | -10 | -9 | |
Depreciation | -11 | -13 | -20 | -21 | -9 | -13 | -17 | -17 | -19 | -22 | |
Taxation | -35 | -48 | -63 | -57 | -55 | -34 | -30 | -31 | -29 | -37 | |
Exceptional Items | -34 | -13 | -74 | ||||||||
PAT | 61 | 100 | 113 | 89 | 127 | 95 | 74 | 23 | 77 | 91 | |
Minority Interest | -1 | -18 | -31 | -30 | -3 | 2 | -5 | -8 | -6 | -2 | |
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 60 | 82 | 82 | 59 | 124 | 97 | 68 | 15 | 71 | 88 | |
Adjusted EPS | 6 | 8 | 8 | 6 | 12 | 9 | 7 | 1 | 7 | 8 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 41 | 38 | 113 | 289 | 18 | 40 | 47 | 64 | 135 | 34 | |
Cash Fr. Inv. | -11 | -29 | -50 | -231 | 50 | -74 | -48 | -47 | -93 | -8 | |
Cash Fr. Finan. | -8 | -42 | -40 | -10 | -76 | 17 | -6 | -21 | -24 | -25 | |
Net Change | 22 | -33 | 23 | 48 | -8 | -17 | -8 | -4 | 19 | 2 | |
Cash & Cash Eqvt | 50 | 5 | 28 | 47 | 37 | 15 | 15 | 13 | 22 | 25 |
Fri, 03 Nov 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication Pursuant to the provision of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith the copies of newspaper advertisement published regarding extract of the Unaudited Financial Results of the Company for the quarter and half year ended September 30 2023 "The Economic Times & The Free Press Journal" an English Daily and "Maharashtra Times & Navshakti" a Regional Daily on November 03 2023. |
Wed, 01 Nov 2023
Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday November 01 2023 We would like to inform you that the Board Meeting of the Company was held today i.e. Wednesday November 01 2023 at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 the Board has considered and approved the following matters amongst others:1. The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30 2023. 2. Investment of INR 30 Crores (Approx.) for Capacity Addition/Inclusion of Semi-Solids Finished formulation at our Palghar Vevoor Unit. The Total Capacity expected is approx. 200 million Units in Semi-Solids Dosage and that is expected to be completed and available for commercial production by end of F. Y 2025-26. This expansion shall be funded by a combination of debt and internal accrual. |
Wed, 01 Nov 2023
Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30 2023 We would like to inform you that the Board Meeting of the Company was held today i.e. Wednesday November 01 2023 at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI Listing Regulations. Enclosed herewith Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30 2023 along with Limited Review Report. |
Fri, 08 Dec 2023 |
|
|
|
|
|